Vancomycin-resistente Enterokokken: Welche Therapieoptionen gibt es?

Abstract

Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

Purification and characterization of bacteriocins-like inhibitory substances from food isolated Enterococcus faecalis OS13 with activity against nosocomial enterococci

“…Most VREs are also resistant to antibiotics as ampicillin, vancomycin, and aminoglycosides, widely used in the hospital environment. Therefore, only a few therapeutic options are commercially available to treat multidrug-resistant VRE infections, including linezolid, tedizolid, tigecycline, and daptomycin 46,47 . The increased use of these last-source antibiotics and the ability of enterococci to readily acquire new resistance determinants are currently raising the need to find alternative therapeutics and explore the effectiveness of natural antimicrobials such as bacteriocins.…”